Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Psilocybin Clear all
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108
View directory record Official record
Conditions
Psilocybin, Music Intervention
Interventions
Psilocybin (high dose), Playlist 1, Playlist 2, Playlist 3, Playlist 4, Playlist 5
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Withdrawn Phase 2 Interventional

PET Synaptogenesis After Psilocybin In DEpression Recovery

NCT05601648
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Psilocybin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 7, 2026, 2:50 AM EDT
Not yet recruiting Phase 1 Interventional

Psilocybin as a Novel Therapy for Residual Anhedonia

NCT07607938
View directory record Official record
Conditions
Anhedonia, Emotional Blunting
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

UW Psilocybin Pharmacokinetics Study

NCT02163707
View directory record Official record
Conditions
Healthy
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jun 7, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT05399498
View directory record Official record
Conditions
Borderline Personality Disorder, Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

Psilocybin Therapy in Advanced Cancer

NCT05398484
View directory record Official record
Conditions
Advanced Cancer
Interventions
Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
La Jolla, California • Jacksonville, Florida • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Not yet recruiting Phase 2 Interventional

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369
View directory record Official record
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Enrolling by invitation Phase 3 Interventional

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

NCT06605105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003
Drug
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Intergenerational Trauma

NCT06899165
View directory record Official record
Conditions
Psychological Stress, Depression, Anxiety
Interventions
Psilocybin, Integration sessions
Drug · Behavioral
Lead sponsor
Rachel Yehuda
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin (0.25mg/kg), Niacin (250mg)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 3 Interventional

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

NCT06564818
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychological Support, Placebo
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Active, not recruiting No phase listed Observational

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

NCT07189988
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
psilocybin
Other
Lead sponsor
Healing Advocacy Fund
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin for Prolonged Grief Disorder

NCT06724289
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI)
Drug · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583
View directory record Official record
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

RCT of Psilocybin-assisted CBT for Depression

NCT07281352
View directory record Official record
Conditions
Major Depressive Diorder
Interventions
Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Psilocybin in Cancer Pain Study

NCT06001749
View directory record Official record
Conditions
Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Interventions
Psilocybin
Drug
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

NCT07216404
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Unipolar Depression
Interventions
Biospecimen Collection, Counseling, Interview, Psilocybin, Survey Administration
Procedure · Other · Drug
Lead sponsor
Alan Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 7, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Jun 7, 2026, 2:50 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

NCT05042466
View directory record Official record
Conditions
Trauma, Nervous System
Interventions
Trauma
Drug
Lead sponsor
NWTraumatherapies
Network
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jun 7, 2026, 2:50 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

NCT07516405
View directory record Official record
Conditions
Healthy Volunteer, Older Adults (65-85 Years)
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 7, 2026, 2:50 AM EDT